Abstract
IntroductionProgress towards leprosy elimination is threatened by increasing incidence in ‘hot-spot’ areas where more effective control strategies are urgently required. In these areas, active case finding and leprosy prevention limited to known contacts is insufficient for control. Population-wide active case-finding together with universal prevention through mass drug administration (MDA) has been shown to be effective in ‘hot-spot’ areas, but is logistically challenging and expensive. Combining leprosy screening and MDA with other population-wide screening activities such as for tuberculosis may increase programme efficiency. There has been limited evaluation of the feasibility and effectiveness of combined screening and MDA interventions. The COMBINE study aims to bridge this knowledge gap.Methods and analysisThis implementation study will assess the feasibility and effectiveness of active leprosy case-finding and treatment, combined with MDA using either single-dose rifampicin or rifamycin-containing tuberculosis preventive or curative treatment, for reducing leprosy incidence in Kiribati. The leprosy programme will run over 2022–2025 in concert with population-wide tuberculosis screening-and-treatment in South Tarawa. The primary research question is to what extent the intervention reduces the annual leprosy new case detection rate (NCDR) in adults and children compared with routine screening and postexposure prophylaxis (PEP) among close contacts (baseline leprosy control activities). Comparisons will be made with (1) the preintervention NCDR separably among adults and children in South Tarawa (before–after study) and (2) the corresponding NCDRs in the rest of the country. Additionally, the postintervention prevalence of leprosy obtained from a survey of a ‘hot-spot’ sub-population will be compared with prevalence documented during the intervention. The intervention will be implemented in collaboration with the Kiribati National Leprosy Programme.Ethics and disseminationApproval has been obtained from the Kiribati Ministry of Health and Medical Services (MHMS), the University of Otago (H22/111) and the University of Sydney (2021/127) Human Research Ethics Committees. Findings will be shared with the MHMS, local communities and internationally through publication.
Funder
Turing Foundation
Pacific Leprosy Foundation
Leprosy Research Initiative
Reference30 articles.
1. World Health Assembly . Resolution to eliminate leprosy as a public health problem by the year 2000 resolution WHA449. Geneva: 44th World Health Assembly, 1991.
2. WHO . World Health Organization leprosy elimination project: status report 2002: world health organization; 2003.
3. World health organization global leprosy (Hansen disease) update, 2020: impact of COVID-19 on global leprosy control;Weekly Epidemiol Rec,2021
4. Urgesa K , Bobosha K , Seyoum B , et al . Evidence for hidden leprosy in a high leprosy-endemic setting, Eastern Ethiopia: the application of active case-finding and contact screening. PLoS Negl Trop Dis 2021;15:e0009640. doi:10.1371/journal.pntd.0009640
5. Evidence of hidden leprosy in a supposedly low endemic area of Brazil;Bernardes;Mem Inst Oswaldo Cruz,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献